- 现金
- 3700 元
- 精华
- 16
- 帖子
- 1790
- 注册时间
- 2002-12-9
- 最后登录
- 2021-4-14
|
1楼
发表于 2005-2-8 04:12
LAMIVUDINE-RESISTANT HBV
Comparison of adefovir and tenofovir. Florian van Bommel et al. analyzed treatment of 53 consecutive patients with lamivudine-resistant HBV infection with either adefovir (n=18) for 60 to 80 weeks or tenofovir (n=35) for 72 to 130 weeks. Of the tenofovir-treated patients, 21 were coinfected with HIV. Tenofovir therapy was associated with an early suppression of HBV DNA, resulting in a reduction of HBV DNA levels at week 48 to <105 copies/mL in 100% of tenofovir-treated patients, vs. 44% of adefovir-treated patients. Both agents were well tolerated, with no evidence of phenotypic resistance. These data suggest that tenofovir may be a potentially effective alternative treatment for patients with lamivudine-resistant HBV infection. Controlled trials with larger numbers of patients are warranted. (van Bommel F, et al. Hepatology 2004;40:1421-1425) |
|